Skip to main content
Advertisement
Home

Main navigation

  • Digital Issue Archive
  • Service Directory
  • Awards
  • Advertise
  • Subscribe now

Secondary

  • Travel Insurance
  • Policies & Partnerships
  • Travel Risk Management
  • Travel Trends
  • Hospitals & Healthcare
  • Industry Moves
  • Reviews
International Hospitals & Healthcare Part of the IH&H family
Part of the
IH&H family
International Hospitals & Healthcare

A new weapon in the fight against dengue fever

Travel Risk Management
14 Jul 2020 | Stefan Mohamed
Share
Mosquitoes are horrible

US researchers have discovered a new mechanism for the design of antiviral drugs to combat the virus, which infects hundreds of millions of people every year

Keep on reading

Someone thoroughly washing their hands

The infectious diseases to be mindful of when global travel resumes

The World Economic Forum has compiled a list of five of the world’s deadliest diseases
16 Apr 2020
|
Lauren Haigh

The team, from the University of Texas Medical Branch, have written up their results in a study published in Proceedings of the National Academy of Sciences. The crux of the breakthrough is that the team was able to analyse and decode the co-crystal structure of the dengue capsid protein, which makes up the core of the virus, in complex with an inhibitor; understanding this structure potentially opens up new potential methods of fighting the virus.

“There are four types of dengue virus, all of which can cause epidemics and disease in humans,” said Pei-Yong Shi, Professor of Human Genetics at the University of Texas Medical Branch. “Using this new information, we will be able to design new drugs that can inhibit all types of dengue virus. In addition, the structural information will also enable us to make compounds with improved potency and drug-like properties.”

Dengue fever is present in various forms in over 100 countries around the world, and a staggering 40 per cent of the global population is at risk of dengue infection. Unsurprisingly, the World Health Organization lists it as a top-10 public health threat, making this a timely intervention.

“Although we are currently coping with the Covid-19 pandemic,” said the study’s lead author, Hongjie Xia, a postdoctoral fellow at the university, “Singapore and other regions are experiencing a record number of dengue human cases. This motivates our team to develop clinical treatments for this devastating disease.”

A mosquito-borne disease, dengue presents with a high fever, along with any two of the following symptoms: severe headache, pain behind the eyes, muscle and joint pains, nausea, vomiting, swollen glands, or a rash. In some cases, it can progress to a more severe infection, potentially leading to permanent damage or death. It is common in many countries that - during normal times at least - have high tourist turnover, such as Thailand; travel insurers wary of such destinations will no doubt be cheered to hear that scientists are taking positive strides to fight another viral menace.

Travel Risk Management
14 Jul 2020
Share

Stefan Mohamed

Stefan Mohamed is the former Deputy Editor of ITIJ. He has over seven years’ experience writing about travel insurance and its ancillary industries. He also writes novels. 

Keep on reading

No results

There are no results available matching your search term.

Why subscribe to ITIJ?

In-depth analysis

In-depth analysis

Unique insights and expert opinions on the latest industry developments

A wider perspective

A wider perspective

Get the global view on the topics that are trending in your region

Breaking news

Breaking news

ITIJ.com has all the latest news relevant to travel insurance and IPMI professionals

Subscribe now
ITIJ IH&H

Footer menu

  • About Us
  • Subscribe
  • Advertise
  • Contact
  • Privacy Policy
  • Terms
  • Voyageur
International Travel & Health Insurance Conferences

Social

  • LinkedIn link
  • Twitter link

© Voyageur Publishing & Events 2026

Close